$XENT on NASDAQ
January 25, 2022
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization
November 02, 2021
Intersect ENT Reports Third Quarter 2021 Financial Results
October 28, 2021
First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
August 06, 2021
Intersect ENT Reports Second Quarter 2021 Financial Results
July 26, 2021
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
July 23, 2021
Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
July 22, 2021
Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan
May 20, 2021
Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
May 10, 2021
Intersect ENT Reports First Quarter 2021 Financial Results
May 07, 2021
Intersect ENT to Participate at Upcoming Investor Conferences
May 04, 2021
Intersect ENT Announces Appointment of New Vice President of Sales
April 29, 2021
Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement
April 29, 2021
EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation
April 20, 2021
Intersect ENT to Report First Quarter 2021 Financial Results
April 05, 2021
Intersect ENT Announces Changes to its Board of Directors
March 11, 2021
Dr. Neil Hattangadi Joins Intersect ENT’s Board of Directors
March 10, 2021
Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference
March 09, 2021
Intersect ENT Reports Fourth Quarter and Full Year 2020 Financial Results
March 08, 2021
CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication
February 23, 2021
Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results
February 11, 2021
Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant
February 01, 2021
Intersect ENT to Participate in Upcoming Investor Conferences
January 19, 2021
Intersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus Implant
January 12, 2021
Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020
December 17, 2020
Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference
November 17, 2020
Intersect ENT Announces New Appointments to Executive Leadership Team
November 05, 2020
Intersect ENT to Participate at Upcoming Investor Conferences
November 02, 2020
Intersect ENT Reports Third Quarter 2020 Financial Results
October 15, 2020
Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020
October 09, 2020
Intersect ENT to Report Third Quarter 2020 Financial Results
October 02, 2020
Intersect ENT Closes Acquisition of Fiagon AG Medical Technologies
September 15, 2020
Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years
September 10, 2020
Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant
August 04, 2020
Intersect ENT Reports Second Quarter 2020 Financial Results
July 22, 2020
Intersect ENT to Report Second Quarter 2020 Financial Results
June 23, 2020
Intersect ENT Announces Independent Analysis in UK Confirming Cost Effectiveness of PROPEL® Steroid Releasing Sinus Implant Following Sinus Surgery for Chronic Sinusitis
June 09, 2020
CMS Approves SINUVA® Sinus Implant for Reimbursement with New C-Code and Pass-Through Payment Status
May 26, 2020
Intersect ENT to Present at the William Blair 40th Annual Growth Stock Conference
May 11, 2020
Intersect ENT Reports First Quarter 2020 Results
May 11, 2020
Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management
May 08, 2020
Intersect ENT Reschedules Time of First Quarter 2020 Financial Results Conference Call to 4:30 P.M. ET on May 11, 2020
May 07, 2020
Intersect ENT to Present at the 2020 Bank of America Merrill Lynch Global Healthcare Conference
April 28, 2020
Intersect ENT to Report First Quarter 2020 Financial Results
April 13, 2020
Intersect ENT Announces Preliminary Revenue for First Quarter 2020 and Provides Business Update in Response to COVID-19 Pandemic
February 24, 2020
Intersect ENT Reports Fourth Quarter and Full Year 2019 Results
February 05, 2020
Intersect ENT to Report Fourth Quarter and Year 2019 Financial Results
February 05, 2020
Intersect ENT to Present at the 9th Annual SVB Leerink Global Healthcare Conference
January 13, 2020
Intersect ENT Reports Preliminary Full Year 2019 Revenue
December 11, 2019
Intersect ENT to Present at the 38th Annual J.P. Morgan Healthcare Conference
November 27, 2019
Intersect ENT Announces Appointment of New Chief Financial Officer
- No Recent Filings Found.
